Table 1.
Baseline characteristics
| Finerenone | Placebo | |
|---|---|---|
| n = 9,501 | n = 9,490 | |
| Age | 67.0 ± 10.0 | 67.1 ± 10.2 |
| Female | 3,390 (35.7%) | 3,274 (34.5%) |
| Racea | ||
| Asian | 1,910 (20.1%) | 1,946 (20.5%) |
| Black | 300 (3.2 %) | 308 (3.2 %) |
| Other | 476 (5.0 %) | 447 (4.7 %) |
| White | 6,815 (71.7%) | 6,789 (71.5%) |
| Region | ||
| Asia | 1,808 (19.0%) | 1,815 (19.1%) |
| Eastern Europe | 3,001 (31.6%) | 2,941 (31.0%) |
| Latin America | 1,041 (11.0%) | 1,034 (10.9%) |
| North America | 1,259 (13.3%) | 1,261 (13.3%) |
| Western Europe, Oceania and Others | 2,392 (25.2%) | 2,439 (25.7%) |
| Body mass index (kg m-2) | 30.9 ± 6.1 | 30.9 ± 6.0 |
| Systolic blood pressure (mmHg) | 134.5 ± 14.9 | 134.4 ± 15.0 |
| Potassium (mmol L-1) | 4.4 ± 0.5 | 4.4 ± 0.5 |
| eGFR (mL min-1 1.73 m-2) | 58.9 ± 21.0 | 59.1 ± 21.3 |
| eGFR category | ||
| <25 mL min-1 1.73 m-2 | 100 (1.1%) | 94 (1.0%) |
| 25 to <45 mL min-1 1.73 m-2 | 2,742 (28.9%) | 2,782 (29.3%) |
| 45 to <60 mL min-1 1.73 m-2 | 2,513 (26.5%) | 2,469 (26.0%) |
| ≥60 mL min-1 1.73 m-2 | 4,145 (43.6%) | 4,143 (43.7%) |
| UACR (mg g-1) | 283 (46–836) | 293 (47–855) |
| Albuminuria category | ||
| A1 (<30 mg g-1) | 1,885 (20.1%) | 1,856 (19.8%) |
| A2 (30 to <300 mg g-1) | 2,910 (31.0%) | 2,883 (30.7%) |
| A3 (≥300 mg g-1) | 4,602 (49.0%) | 4,646 (49.5%) |
| Hemoglobin A1c (%) | 7.3 ± 1.4 | 7.3 ± 1.4 |
| AF on electrocardiogram | 1,449 (15.3%) | 1,379 (14.5%) |
| History of HFb | 3,488 (36.7%) | 3,520 (37.1%) |
| Baseline CKDc | 7,949 (83.7%) | 7,929 (83.6%) |
| History of DMd | 7,715 (81.2%) | 7,714 (81.3%) |
| Background medication use | ||
| Diuretics | 6,291 (66.2%) | 6,340 (66.8%) |
| ACEi/ARB/ARNI | 8,866 (93.3%) | 8,860 (93.4%) |
| Aspirin | 4,145 (43.6%) | 4,171 (44.0%) |
| Statins | 6,687 (70.4%) | 6,750 (71.1%) |
| SGLT-2 inhibitors | 829 (8.7%) | 861 (9.1%) |
| GLP-1 receptor agonists | 576 (6.1%) | 534 (5.6%) |
| Potassium-lowering therapiese | 99 (1.0%) | 96 (1.0%) |
A1, A2 and A3, albuminuria categories; ACEi, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; DM, diabetes mellitus.
aRepresents self-reported race. Participants choosing not to disclose race or who self-identified as multiple races are included in the ‘Other’ category for descriptive purposes.
bHF includes all participants in FINEARTS-HF and those with investigator-reported history of HF in the primary CKD outcomes trials (FIDELIO-DKD and FIGARO-DKD).
cCKD includes all participants in the primary CKD outcomes trials (FIDELIO-DKD and FIGARO-DKD) and participants in FINEARTS-HF with baseline eGFR of <60 ml min−1 1.73 m−2.
dDiabetes includes all participants in the primary CKD outcomes trials (FIDELIO-DKD and FIGARO-DKD) and those with a history of diabetes in FINEARTS-HF.
eIncludes patiromer, sodium polystyrene sulfonate and calcium polystyrene sulfonate.